人附睾蛋白4与CA125联合检测对卵巢上皮癌诊断价值.docVIP

人附睾蛋白4与CA125联合检测对卵巢上皮癌的诊断价值 　　【摘要】 目的：探讨人附睾蛋白4（HE4）联合血清CA125用于卵巢上皮性癌诊断的临床价值。方法：选取本院收治住院并经手术及病理检查确诊的卵巢上皮性肿瘤患者165例，用ELISA法检测血清中CA125水平和血液HE4水平，其中87例患者为卵巢上皮性癌组，78例患者为卵巢良性肿瘤组，50例同期健康体检女性为对照组。结果：卵巢上皮癌患者组血液中HE4水平明显高于卵巢良性肿瘤组及对照组，差异均有统计学意义（P0.05）；血液中HE4检测卵巢上皮性癌的灵敏度、特异度分别为87.3%、92.3%，与血清CA125联合检测其灵敏度、特异度提高至96.5%、97.4%，差异有统计学意义（P0.05）。结论：联合检测血液中HE4与血清CA125可显著提高卵巢上皮性癌的诊断率。 　　【关键词】 人附睾蛋白4； CA125； 卵巢上皮癌 　　【Abstract】 Objective： To investigated the level of application value of combined detection HE4 and CA125 in serum for the diagnosis of ovarian epithelial tumors.Method： 165 patients with ovarian tumor were selected，87 cases were ovarian epithelial cancers group，78 cases were benign ovarian tumors group and 50 cases were healthy women as control group，and all of them were detected by the methods of ELISA of CA125 in serum and HE4 in blood.Result： The level of HE4 in blood with epithelial ovarian cancer patients were significantly higher than that in benign ovarian tumor group and the control group，the difference was statistically significant（P0.05）. The sensitivity and accuracy of HE4 in blood were 87.3% and 92.3% respectively，the sensitivity and accuracy reached up to 96.5% and 97.4% by combined detection of HE4 in blood and CA125 in serum，the difference was statistically significant（P0.05）.Conclusion： The diagnostic rate of ovarian epithelial cancer can be improved significantly by combined detection of HE4 in blood and CA125 in serum. 　　【Key words】 Human epididymis protein 4； CA125； Ovarian epithelial cancer 　　First-author’s address：Dongguan People’s Hospital，Dongguan 523059，China 　　doi：10.3969/j.issn.1674-4985.2015.07.009 　　卵巢癌是女性生殖器官三大恶性肿瘤之一，恶性程度高、发展迅速，以卵巢上皮性癌最为常见，占卵巢恶性肿瘤的85%～90%[1]。因癌抗原125（CA125）对卵巢上皮癌初期诊断的灵敏度和特异度较低，部分良性疾病和生理情况下也可能发生轻度升高，故选择新的生化标志物用于诊断卵巢上皮癌尤其必要。近年来相关文献报道人附睾蛋白4（HE4）是一种新型的肿瘤标志物，在卵巢癌诊断、监测方面得到学者们的关注[2]。本文研究165例卵巢肿瘤患者血液HE4、血清CA125水平，探讨两者联合检测用于诊断卵巢上皮癌的特异性和准确性。 　　1 资料与方法 　　1.1 一般资料 选择2012年1月-2013年12月本院收治住院并经手术及病理检查确诊的卵巢上皮性肿瘤患者165例。按病理类型分为两组：上皮性卵巢癌组87例（浆